{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:44:21Z","timestamp":1792172661323,"version":"4.4.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Risk factors for adverse drug reactions (ADRs) associated with prophylactic sulfamethoxazole-trimethoprim (SMX\/TMP) in patients with rheumatic and musculoskeletal diseases undergoing immunosuppressive therapy remain unclear; we aimed to identify the risk factors associated with ADRs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients with rheumatic and musculoskeletal diseases, who were admitted to Keio University Hospital and received prophylactic administration of SMX\/TMP, were included. Data regarding ADRs to SMX\/TMP were collected to identify the associated risk factors using multivariable analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 438 patients included in the analysis, 82 (18.7%) experienced ADRs. Patients in the ADR group were significantly older, had chronic kidney disease, and exhibited lower lymphocyte and platelet counts, lower albumin levels, lower estimated glomerular filtration rates, higher aspartate aminotransferase levels, and higher ferritin levels than those in the non-ADR group. Regarding the underlying rheumatic and musculoskeletal diseases, adult-onset Still\u2019s disease (ASD) was associated with a significantly higher incidence of ADRs (67%) than other diseases. Multivariable analysis identified the presence of ASD and low lymphocyte counts as independent risk factors for allergic ADRs and older age and use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers for nonallergic ADRs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Risk factors for ADRs associated with prophylactic SMX\/TMP treatment in patients with rheumatic and musculoskeletal diseases were identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae059","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T04:45:24Z","timestamp":1722833124000},"page":"94-101","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9278-7751","authenticated-orcid":false,"given":"Kazuoto","family":"Hiramoto","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"2025020515453301400_R1","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"2025020515453301400_R2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrmicro1621","article-title":"Current insights into the biology and pathogenesis of Pneumocystis pneumonia","volume":"5","author":"Thomas","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"2025020515453301400_R3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.medmal.2014.01.007","article-title":"Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients","volume":"44","author":"Roux","year":"2014","journal-title":"Med Mal Infect"},{"key":"2025020515453301400_R4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"2025020515453301400_R5","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1206-8","article-title":"Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial","volume":"19","author":"Utsunomiya","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025020515453301400_R6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/s10165-012-0625-x","article-title":"Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases","volume":"23","author":"Maezawa","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2025020515453301400_R7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim-sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ"},{"key":"2025020515453301400_R8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00296-021-04945-w","article-title":"Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids","volume":"42","author":"Jinno","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025020515453301400_R9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciy154","article-title":"Pneumocystis cytochrome b mutants associated with atovaquone prophylaxis failure as the cause of pneumocystis infection outbreak among heart transplant recipients","volume":"67","author":"Argy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025020515453301400_R10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0961203307086640","article-title":"Sulpha allergy in lupus patients: a clinical perspective","volume":"17","author":"Jeffries","year":"2008","journal-title":"Lupus"},{"key":"2025020515453301400_R11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/14397595.2015.1112467","article-title":"Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: a retrospective cohort study","volume":"26","author":"Suyama","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2025020515453301400_R12","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1177\/09612033211033985","article-title":"Adverse drug reactions to trimethoprim-sulfamethoxazole in systemic lupus erythematosus","volume":"30","author":"Izuka","year":"2021","journal-title":"Lupus"},{"key":"2025020515453301400_R13","first-page":"238","article-title":"Renal salt wasting and metabolic acidosis with trimethoprim-sulfamethoxazole therapy","volume":"50","author":"Kaufman","year":"1983","journal-title":"Mt Sinai J Med"},{"key":"2025020515453301400_R14","first-page":"215","article-title":"Update on diagnosis and treatment of resistant hypertension","volume":"5","author":"Pimenta","year":"2011","journal-title":"Iran J Kidney Dis"},{"key":"2025020515453301400_R15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000328911","article-title":"Trimethoprim, creatinine and creatinine-based equations","volume":"119","author":"Delanaye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"2025020515453301400_R16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025020515453301400_R17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.166.2.945","article-title":"IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells","volume":"166","author":"Leite-De-Moraes","year":"2001","journal-title":"J Immunol"},{"key":"2025020515453301400_R18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bjp.0704074","article-title":"Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo","volume":"133","author":"Naisbitt","year":"2001","journal-title":"Br J Pharmacol"},{"key":"2025020515453301400_R19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol Pharmacol"},{"key":"2025020515453301400_R20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.597761","article-title":"The roles of immunoregulatory networks in severe drug hypersensitivity","volume":"12","author":"Hsu","year":"2021","journal-title":"Front Immunol"},{"key":"2025020515453301400_R21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00130832-200208000-00004","article-title":"Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions","volume":"2","author":"Reilly","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae059\/58970849\/roae059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/94\/58970849\/roae059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/94\/58970849\/roae059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:45:48Z","timestamp":1738770348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/1\/94\/7727263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,5]]},"published-print":{"date-parts":[[2024,12,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae059","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,5]]}}}